PMID- 36289885
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221030
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 10
IP  - 10
DP  - 2022 Oct 19
TI  - Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19.
LID - 10.3390/biomedicines10102624 [doi]
LID - 2624
AB  - The present study aimed to analyse the published data and to realize an update 
      about the use and pathogenesis of the novel antidiabetic drugs, respectively, 
      dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor 
      agonists (GLP-1 Ra), and sodium-glucose co-transporter-2 inhibitors (SGLT-2i), in 
      patients with type 2 diabetes mellitus (T2DM) and coronavirus disease (COVID-19). 
      Literature research in the PubMed and Web of Science database was performed in 
      order to identify relevant published clinical trials and meta-analyses that 
      include information about the treatment with novel antidiabetic agents in 
      patients with T2DM and COVID-19. A total of seven articles were included, and 
      their primary and secondary outcomes were reported and analysed. DPP-4i has mixed 
      results on mortality in T2DM patients with COVID-19 but with an overall slightly 
      favourable or neutral effect, whereas GLP-1 Ra seems to have a rather beneficial 
      impact, while SGLT-2i may be useful in acute illness. Even if there are limited 
      data, they seem to have favourable efficacy and safety profiles. The available 
      evidence is heterogenous and insufficient to evaluate if the benefits of 
      non-insulin novel antidiabetic drugs in COVID-19 treatment are due to the 
      improvement of glycaemic control or to their intrinsic anti-inflammatory effects 
      but highlights their beneficial effects in the pathogenesis and evolution of the 
      disease.
FAU - Salmen, Teodor
AU  - Salmen T
AUID- ORCID: 0000-0003-4548-7441
AD  - Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 020021 
      Bucharest, Romania.
FAU - Pietrosel, Valeria-Anca
AU  - Pietrosel VA
AD  - Department of Diabetes, Nutrition and Metabolic Diseases, "Prof. Dr N.C.Paulescu" 
      National Institute of Diabetes, Nutrition and Metabolic Diseases, 030167 
      Bucharest, Romania.
FAU - Mihai, Bianca-Margareta
AU  - Mihai BM
AD  - Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 020021 
      Bucharest, Romania.
FAU - Bica, Ioana Cristina
AU  - Bica IC
AD  - Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 020021 
      Bucharest, Romania.
FAU - Teodorescu, Claudiu
AU  - Teodorescu C
AD  - Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 020021 
      Bucharest, Romania.
FAU - Paunescu, Horia
AU  - Paunescu H
AUID- ORCID: 0000-0002-6084-1974
AD  - Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, "Carol 
      Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
FAU - Coman, Oana Andreia
AU  - Coman OA
AD  - Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, "Carol 
      Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
FAU - Mihai, Doina-Andrada
AU  - Mihai DA
AD  - Department of Diabetes, Nutrition and Metabolic Diseases, "Prof. Dr N.C.Paulescu" 
      National Institute of Diabetes, Nutrition and Metabolic Diseases, 030167 
      Bucharest, Romania.
AD  - Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University 
      of Medicine and Pharmacy, Bld. Eroii Sanitari No. 8, 050471 Bucharest, Romania.
FAU - Pantea Stoian, Anca
AU  - Pantea Stoian A
AUID- ORCID: 0000-0003-0555-526X
AD  - Department of Diabetes, Nutrition and Metabolic Diseases, "Prof. Dr N.C.Paulescu" 
      National Institute of Diabetes, Nutrition and Metabolic Diseases, 030167 
      Bucharest, Romania.
AD  - Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University 
      of Medicine and Pharmacy, Bld. Eroii Sanitari No. 8, 050471 Bucharest, Romania.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221019
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC9599217
OTO - NOTNLM
OT  - COVID-19
OT  - dipeptidyl peptidase-4 inhibitors
OT  - glucagon-like peptide-1 receptor agonist
OT  - pathogenesis
OT  - sodium-glucose co-transporter-2 inhibitors
COIS- Anca Pantea Stoian is currently the President of Romanian National Diabetes 
      Committee, and she has given lectures, received honoraria and research support, 
      and participated in conferences, advisory boards, and clinical trials sponsored 
      by pharmaceutical companies, including AstraZeneca, Boehringer Ingelheim, 
      Medtronic, Eli Lilly, Merck, Novo Nordisk, Novartis, Roche Diagnostics, and 
      Sanofi. Doina-Andrada Mihai has given lectures, received honoraria and 
      participated clinical trials sponsored by pharmaceutical companies, including 
      AstraZeneca, Boehringer Ingelheim, Medtronic, Eli Lilly, Novo Nordisk, Servier, 
      and Sanofi. The rest of the authors declare no conflict of interest.
EDAT- 2022/10/28 06:00
MHDA- 2022/10/28 06:01
PMCR- 2022/10/19
CRDT- 2022/10/27 01:03
PHST- 2022/09/19 00:00 [received]
PHST- 2022/10/09 00:00 [revised]
PHST- 2022/10/11 00:00 [accepted]
PHST- 2022/10/27 01:03 [entrez]
PHST- 2022/10/28 06:00 [pubmed]
PHST- 2022/10/28 06:01 [medline]
PHST- 2022/10/19 00:00 [pmc-release]
AID - biomedicines10102624 [pii]
AID - biomedicines-10-02624 [pii]
AID - 10.3390/biomedicines10102624 [doi]
PST - epublish
SO  - Biomedicines. 2022 Oct 19;10(10):2624. doi: 10.3390/biomedicines10102624.